All Content Outsourced Pharma

31. Regulatory Flexibility in CGT: Key Shifts and Implications with Monika Swietlicka 3/24/2026

    On episode 125 of Cell & Gene: The Podcast, Host Erin Harris talks to Halloran Consulting Group's Monika Swietlicka to discuss how the FDA is increasing flexibility in cell and gene therapy development without lowering evidentiary standards, emphasizing a risk-based, holistic approach.

32. Engineering The Next Wave Of CHO Performance 3/24/2026

    By combining improved productivity with speed and reliability, S-CHOice® 2G helps biopharmaceutical companies optimize their manufacturing strategies, reduce overall costs, and respond more effectively to market demands.

33. Pace Life Sciences Capabilities Update March 2026: Analytical Services 3/24/2026

    A CDMO leader highlights two decades of growth, showcasing analytical strength, manufacturing, regulatory support, and integrated services that speed drug development.

34. Solvias Capabilities Update March 2026: Analytical Services 3/24/2026

    A biotech leader highlights end‑to‑end analytical capabilities from development to commercialization, with expertise in biologics, gene therapies, quality testing, and regulatory solutions.

35. Catalent Capabilities Update March 2026: Analytical Services 3/24/2026

    A biologics analytics leader showcases development, testing, and characterization capabilities, emphasizing quality, regulatory compliance, and integrated support from discovery to commercialization.

36. Minaris Advanced Therapies Capabilities Update March 2026: Cell & Gene Therapy 3/24/2026

    A global CDMO specializing in cell and gene therapies, offering end-to-end development, manufacturing, and testing services with over 25 years of expertise and personalized client support.

37. Lonza Capabilities Update March 2026: Cell & Gene Therapy 3/24/2026

    A global CDMO outlines end-to-end capabilities in cell and gene therapy, mRNA, and microbial platforms, emphasizing scalability, innovation, and seamless development through commercial manufacturing.

38. Landmark Bio Capabilities Update March 2026: Cell & Gene Therapy 3/24/2026

    A translational CDMO approach integrates development, analytics, and GMP manufacturing to streamline cell and gene therapy advancement from early research through scalable clinical production.

39. Comprehensive Cell Solutions Capabilities Update March 2026: Cell & Gene Therapy 3/24/2026

    An integrated draw‑to‑thaw CDMO model connecting donor sourcing, development, GMP manufacturing, and cryogenic storage to streamline workflows, strengthen quality control, and speed clinical readiness.

40. Recipharm Advanced Bio Capabilities Update March 2026: Analytical Services 3/24/2026

    A lifecycle‑based analytical framework supporting release testing, stability studies, and product characterization to boost regulatory readiness, cut variability, and speed development.